[go: up one dir, main page]

WO2015165980A3 - Treatment and prevention of alzheimer's disease (ad) - Google Patents

Treatment and prevention of alzheimer's disease (ad) Download PDF

Info

Publication number
WO2015165980A3
WO2015165980A3 PCT/EP2015/059364 EP2015059364W WO2015165980A3 WO 2015165980 A3 WO2015165980 A3 WO 2015165980A3 EP 2015059364 W EP2015059364 W EP 2015059364W WO 2015165980 A3 WO2015165980 A3 WO 2015165980A3
Authority
WO
WIPO (PCT)
Prior art keywords
prevention
treatment
alzheimer
disease
monocyte
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2015/059364
Other languages
French (fr)
Other versions
WO2015165980A2 (en
Inventor
Markus Mandler
Radmila Santic
Achim Schneeberger
Frank Mattner
Walter Schmidt
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Affiris AG
Original Assignee
Affiris AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Affiris AG filed Critical Affiris AG
Publication of WO2015165980A2 publication Critical patent/WO2015165980A2/en
Publication of WO2015165980A3 publication Critical patent/WO2015165980A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/15—Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cells; Myeloid precursor cells; Antigen-presenting cells, e.g. dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0007—Nervous system antigens; Prions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6081—Albumin; Keyhole limpet haemocyanin [KLH]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Microbiology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The invention discloses a monocyte inducing agent and/or a monocyte activating agent and/or a monocyte recruiting agent for use in the treatment and prevention of AD.
PCT/EP2015/059364 2014-04-29 2015-04-29 Treatment and prevention of alzheimer's disease (ad) Ceased WO2015165980A2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP14166355.9 2014-04-29
EP14166386.4 2014-04-29
EP14166386 2014-04-29
EP14166355 2014-04-29

Publications (2)

Publication Number Publication Date
WO2015165980A2 WO2015165980A2 (en) 2015-11-05
WO2015165980A3 true WO2015165980A3 (en) 2016-02-04

Family

ID=53039900

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2015/059364 Ceased WO2015165980A2 (en) 2014-04-29 2015-04-29 Treatment and prevention of alzheimer's disease (ad)

Country Status (1)

Country Link
WO (1) WO2015165980A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9649335B1 (en) * 2016-03-30 2017-05-16 Baylor University Intravenous administration of an oxygen-enabled fluid
CN111727260A (en) * 2019-10-15 2020-09-29 湖南乾康科技有限公司 Application of intermediate monocytes in preparation of drugs for diagnosis and prediction of AD
CN117122612B (en) * 2023-07-07 2024-08-27 河络新图生物科技(上海)有限公司 Application of peripheral blood mononuclear cells in preparation of medicines for treating/preventing Alzheimer disease
CN118924788B (en) * 2024-05-28 2025-02-07 昆明医科大学 Application of tumor-derived monocytes

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012055981A1 (en) * 2010-10-27 2012-05-03 Glaxosmithkline Biologicals S.A. Immunogenic compositions and methods for treating neurologic disorders

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012055981A1 (en) * 2010-10-27 2012-05-03 Glaxosmithkline Biologicals S.A. Immunogenic compositions and methods for treating neurologic disorders

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
JOHANNA MAGGA ET AL: "Production of monocytic cells from bone marrow stem cells: therapeutic usage in Alzheimer's disease", JOURNAL OF CELLULAR AND MOLECULAR MEDICINE, vol. 16, no. 5, 26 April 2012 (2012-04-26), pages 1060 - 1073, XP055143513, ISSN: 1582-1838, DOI: 10.1111/j.1582-4934.2011.01390.x *
LEBSON L A ET AL: "Monocyte gene therapy in Alzheimer's disease APP+PS1 transgenic mice", CELL TRANSPLANTATION, COGNIZANT COMMUNICATION CORP, US, vol. 17, no. 4, 2008, pages 470 - 471, XP009180477, ISSN: 0963-6897 *
TARJA MALM ET AL: "The role and therapeutic potential of monocytic cells in Alzheimer's disease", GLIA, 12 February 2010 (2010-02-12), pages NA - NA, XP055143504, ISSN: 0894-1491, DOI: 10.1002/glia.20973 *

Also Published As

Publication number Publication date
WO2015165980A2 (en) 2015-11-05

Similar Documents

Publication Publication Date Title
IL271492A (en) Use of cannabidiol in the treatment of tuberous sclerosis complex
GB2548873B (en) Use of Cannabidiol in the Treatment of SturgeWeber Syndrome
PL3577135T3 (en) A pharmaceutical composition for use in the treatment or prevention of c5-related diseases
GB201411496D0 (en) Use of 7-Oh-Cannabidiol (7-Oh-CBD) and/or 7-Oh-Cannabidvarin (7-Oh-CBDV) in the treatment of epilepsy
IL254142B (en) Tradipitant for use in the treatment of a tradipitant-responsive disease or condition
WO2017044807A3 (en) Reduction of er-mam-localized app-c99 and methods of treating alzheimer's disease
GB2564459B (en) Use of cannabinoids in the treatment of a neurodegenerative disease or disorder
EP3261446A4 (en) Methods and compositions for the treatment or prevention of parkinson's disease
WO2015165980A3 (en) Treatment and prevention of alzheimer's disease (ad)
SI3668856T1 (en) Novel tetrazole compounds and their use in the treatment of tuberculosis
WO2015106108A3 (en) Novel functionalized 1,3-benzene diols and their method of use for the treatment of hepatic encephalopathy
IL274838A (en) Use of mir101 or mir128 in the treatment of seizure disorders
HUE056265T2 (en) Igmesine for use in the treatment of alzheimer's disease
PL3137097T3 (en) Treatment and prevention of alzheimer's disease (ad)
IL254252A0 (en) Tetrahydrofurane-fused aminohydrothiazine derivatives which are useful in the treatment of alzheimer's disease
PT3137094T (en) Treatment and prevention of alzheimer's disease (ad)
PL3166660T3 (en) Substances and methods for the use in prevention and/or treatment in huntington's disease
EP3646872A4 (en) Agent for preventing and/or treating alzheimer's disease
CY1119674T1 (en) Alzheimer's Disease Treatment and Prevention (AD)
EP3162377A4 (en) Use of -asarone in preparing drugs for preventing and treating alzheimer's disease
ITUA20163037A1 (en) Formulations for use in the treatment or prevention of urological disorders
HK40036650A (en) Use of mir101 or mir128 in the treatment of seizure disorders
HK40038525A (en) Use of cannabinoids in the treatment of epilepsy
HK40009492A (en) Agents and methods for the prevention or treatment of h. pylori infections
HK1248110A1 (en) Plx-8394 or plx-7904 for use in the treatment of braf-v600-related diseases

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 15720064

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 15720064

Country of ref document: EP

Kind code of ref document: A2